Beta

Annovis bio, inc.ANVS.US Overview

US StockHealthcare
(No presentation for ANVS)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ANVS AI Insights

ANVS Overall Performance

ANVS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ANVS Recent Performance

-2.12%

Annovis bio, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ANVS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ANVS's Trend

ANVS Key Information

ANVS Valuation Metrics

ANVS Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Price of ANVS

ANVS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.71
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.71
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ANVS's latest earnings report released?

    The most recent financial report for Annovis bio, inc. (ANVS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANVS's short-term business performance and financial health. For the latest updates on ANVS's earnings releases, visit this page regularly.

  • How much cash does ANVS have?

    At the end of the period, Annovis bio, inc. (ANVS) held Total Cash and Cash Equivalents of 19.53M, accounting for 0.93 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ANVS's EPS continuing to grow?

    According to the past four quarterly reports, Annovis bio, inc. (ANVS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ANVS?

    Annovis bio, inc. (ANVS)'s Free Cash Flow (FCF) for the period is -8.93M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ANVS?

    The latest valuation data shows Annovis bio, inc. (ANVS) has a Price-To-Earnings (PE) ratio of -2.48 and a Price/Earnings-To-Growth (PEG) ratio of -0.27. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

ANVS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1